Posted by Michael Wonder on 17 Jul 2017
Institute for Clinical and Economic Review's final evidence report finds prices of anabolic agents for osteoporosis too high, not aligned with potential benefits over other treatments
17 July 2017 - Policy recommendations highlight need for prices to align with clinical benefit, clear guidelines to define highest fracture risk, and broad coverage criteria for patients who may benefit from earlier treatment with anabolic agents.
The Institute of Clinical and Economic Review (ICER) has issued a final evidence report assessing the comparative clinical effectiveness and value of teriparatide (Forteo) and abaloparatide (Tymlos, Radius Health).
The report also includes a summary of a public meeting of the California Technology Assessment Forum (CTAF), during which the independent CTAF Panel deliberated and voted on evidence presented in ICER's report.
